The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

DexCom (DXCM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the ...

DexCom's DXCM shares have risen 6.9% since Tuesday last week, while yesterday’s after-market movement took the rally to nearly 8%. Last week, the company presented a positive picture for its ...

It has been about a month since the last earnings report for DexCom (DXCM). Shares have lost about 7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance. DexCom's steep valuation is only justifiable with sustained ...

Analysts have set 12-month price targets for DexCom, revealing an average target of $97.15, a high estimate of $106.00, and a ...

Valued at a market cap of $25.5 billion, DexCom, Inc. (DXCM) is a medical device company that designs, develops, and ...

DexCom recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact its ability to ...

SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 ...

San Diego’s Dexcom delivered mixed financial results for its fourth quarter, as the continuous glucose monitor maker navigated COVID-19 headwinds and increased costs that weighed on its bottom line.

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by ...